{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hematopoietic+Progenitor+Cell+Infusion&page=5", "query": { "intervention": "Hematopoietic Progenitor Cell Infusion", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 654, "total_pages": 66, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hematopoietic+Progenitor+Cell+Infusion&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hematopoietic+Progenitor+Cell+Infusion&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T00:20:24.963Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01625351", "title": "A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ewing Sarcoma", "Gastrointestinal Tumor", "Germ Cell Tumor", "Hepatic Tumor", "Lymphoma", "Wilms Tumor", "Rhabdoid Tumor", "Clear Cell Carcinoma", "Renal Cell Carcinoma", "Melanoma", "Neuroblastoma", "Rhabdomyosarcoma", "Non-rhabdomyosarcoma" ], "interventions": [ { "name": "alemtuzumab", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "stem cells", "type": "BIOLOGICAL" }, { "name": "CliniMACS", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 23, "start_date": "2012-08-20", "completion_date": "2020-02-10", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-10T00:20:24.963Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01625351" }, { "nct_id": "NCT06679829", "title": "A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Siltuximab", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 215, "start_date": "2024-11-06", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-10T00:20:24.963Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06679829" }, { "nct_id": "NCT05130827", "title": "Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Plinabulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 17, "start_date": "2021-12-21", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-10-10T00:20:24.963Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05130827" }, { "nct_id": "NCT04140539", "title": "A Clinical Study to Enable Process Validation of Commercial Grade OTL-101", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Severe Combined Immunodeficiency Due to ADA Deficiency" ], "interventions": [ { "name": "OTL-101", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Days", "maximum_age": "17 Years", "sex": "ALL", "summary": "30 Days to 17 Years" }, "enrollment_count": 0, "start_date": "2019-10-15", "completion_date": "2021-08-30", "has_results": false, "last_update_posted_date": "2022-08-03", "last_synced_at": "2026-10-10T00:20:24.963Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04140539" }, { "nct_id": "NCT03298412", "title": "Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High-risk Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 10, "start_date": "2018-05-23", "completion_date": "2019-09-30", "has_results": true, "last_update_posted_date": "2020-09-11", "last_synced_at": "2026-10-10T00:20:24.963Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Maywood, Illinois • Cleveland, Ohio + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03298412" }, { "nct_id": "NCT00490529", "title": "Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Mantle-Cell" ], "interventions": [ { "name": "CpG-MCL vaccine", "type": "BIOLOGICAL" }, { "name": "PF-3512676", "type": "BIOLOGICAL" }, { "name": "Vaccine-primed T-cells", "type": "PROCEDURE" }, { "name": "Autologous hematopoietic stem cell transplant (HSCT)", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Standard induction chemotherapy", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Ronald Levy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 59, "start_date": "2009-08", "completion_date": "2017-12-14", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-10-10T00:20:24.963Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00490529" }, { "nct_id": "NCT06514898", "title": "Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Group 3 Medulloblastoma", "Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma" ], "interventions": [ { "name": "TTRNA-DC vaccines with GM-CSF", "type": "BIOLOGICAL" }, { "name": "TTRNA-xALT", "type": "BIOLOGICAL" }, { "name": "Td vaccine", "type": "DRUG" }, { "name": "autologous HSCs", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "4 Years to 30 Years" }, "enrollment_count": 12, "start_date": "2025-05-05", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-10T00:20:24.963Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Gainesville, Florida", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06514898" }, { "nct_id": "NCT02790515", "title": "Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia (ALL)", "Acute Myeloid Leukemia (AML)", "Myeloid Sarcoma", "Chronic Myeloid Leukemia (CML)", "Juvenile Myelomonocytic Leukemia (JMML)", "Myelodysplastic Syndrome (MDS)", "Non-Hodgkin Lymphoma (NHL)" ], "interventions": [ { "name": "Anti-thymocyte globulin (rabbit)", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "HPC,A Infusion", "type": "BIOLOGICAL" }, { "name": "CliniMACS", "type": "DEVICE" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 170, "start_date": "2016-07-14", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-10-10T00:20:24.963Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02790515" }, { "nct_id": "NCT00499889", "title": "Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Fludarabine (Fludara)", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Antithymocyte Globulin (ATG)", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Donor lymphocyte infusion (DLI)", "type": "PROCEDURE" }, { "name": "Stem Cell Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 42, "start_date": "2003-02", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2012-04-23", "last_synced_at": "2026-10-10T00:20:24.963Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499889" }, { "nct_id": "NCT04095858", "title": "Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hematopoietic Stem Cell Transplantation", "Acute Graft Versus Host Disease", "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Efprezimod alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2021-01-05", "completion_date": "2021-11-05", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-10T00:20:24.963Z", "location_count": 4, "location_summary": "Duarte, California • Chicago, Illinois • Hershey, Pennsylvania + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04095858" } ] }